Comparative effects of incretin-based therapy on doxorubicin-induced nephrotoxicity in rats: the role of SIRT1/Nrf2/NF-κB/TNF-α signaling pathways
Frontiers in Pharmacology · 19.02.2024 · 15
DOI: 10.3389/fphar.2024.1353029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.02.2024. Verfasst von Sandy R Botros und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia, Egypt. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Nephrotoxicity represents a major complication of using doxorubicin (DOX) in the management of several types of cancers. Increased oxidative stress and the activation of inflammatory mediators play outstanding roles in the development of DOX-induced kidney damage. This study aimed to investigate whether the two pathways of incretin-based therapy, glucagon-like peptide-1 receptor agonist (presented as semaglutide, SEM) and dipeptidyl peptidase-4 inhibitor (presented as alogliptin, ALO), differentially protect against DOX-induced nephrotoxicity in rats and to clarify the underlying molecular mechanisms.
Methods
Adult male rats were divided into six groups: control (received the vehicle), DOX (20 mg/kg, single I.P. on day 8), DOX + ALO (20 mg/kg/day, P.O. for 10 days), DOX + SEM (12 μg/kg/day, S.C. for 10 days), ALO-alone, and SEM-alone groups. At the end of the study, the animals were sacrificed and their kidney functions, oxidative stress, and inflammatory markers were assessed. Kidney sections were also subjected to histopathological examinations.
Results
The co-treatment with either ALO or SEM manifested an improvement in the kidney functions, as evidenced by lower serum concentrations of creatinine, urea, and cystatin C compared to the DOX group. Lower levels of MDA, higher levels of GSH, and increased SOD activity were observed in either ALO- or SEM-treated groups than those observed in the DOX group. DOX administration resulted in decreased renal expressions of sirtuin 1 (SIRT1) and Nrf2 with increased NF-κB and TNF-α expressions, and these effects were ameliorated by treatment with either ALO or SEM.
Discussion
Co-treatment with either ALO or SEM showed a renoprotective effect that was mediated by their antioxidant and anti-inflammatory effects via the SIRT1/Nrf2/NF-κB/TNF-α pathway. The fact that both pathways of the incretin-based therapy demonstrate an equally positive effect in alleviating DOX-induced renal damage is equally noteworthy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia, Egypt.
- College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Zitieren
APA
Botros, S. R., Matouk, A. I., Amin, A., & Heeba, G. H. (2024). Comparative effects of incretin-based therapy on doxorubicin-induced nephrotoxicity in rats: the role of SIRT1/Nrf2/NF-κB/TNF-α signaling pathways. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1353029
Vancouver
Botros SR, Matouk AI, Amin A, Heeba GH. Comparative effects of incretin-based therapy on doxorubicin-induced nephrotoxicity in rats: the role of SIRT1/Nrf2/NF-κB/TNF-α signaling pathways. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1353029
BibTeX
@article{Botros2024,
author = {Botros, Sandy R and Matouk, Asmaa I and Amin, Amr and Heeba, Gehan H},
title = {Comparative effects of incretin-based therapy on doxorubicin-induced nephrotoxicity in rats: the role of SIRT1/Nrf2/NF-κB/TNF-α signaling pathways},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1353029}
}
EUVIMED